Latest Technology Platform Development News

Praemium plans a staged rollout of its new core technology platform this year, following the integration of Technotia Laboratories. The company has restructured its tech team to cut costs and revised incentive payments for two founding Technotia principals transitioning to consulting roles.

Mesoblast has acquired exclusive rights to a patented chimeric antigen receptor platform designed to enhance the targeting and potency of its mesenchymal stromal cell therapies, aiming to expand treatment options for inflammatory and autoimmune diseases.

Axtec Limited maintains a steady cash position through strategic equity placements and cost reductions while advancing its PropTech platform and partnerships.